Advanced MR Neuroimaging
Series in Medical Physics and Biomedical Engineering
Series Editors: John G. Webster, E. Russell Ritenour, Slavik Tabakov, and Kwan-Hoong Ng
Recent books in the series:
Advanced MR Neuroimaging: From Theory to Clinical Practice
Ioannis Tsougos
Quantitative MRI of the Brain: Principles of Physical Measurement, Second edition
Mara Cercignani, Nicholas G. Dowell, and Paul S. Tofts (Eds)
A Brief Survey of Quantitative EEG
Kaushik Majumdar
Handbook of X-ray Imaging: Physics and Technology
Paolo Russo (Ed)
Graphics Processing Unit-Based High Performance Computing in Radiation Therapy
Xun Jia and Steve B. Jiang (Eds)
Targeted Muscle Reinnervation: A Neural Interface for Artificial Limbs
Todd A. Kuiken, Aimee E. Schultz Feuser, and Ann K. Barlow (Eds)
Emerging Technologies in Brachytherapy
William Y. Song, Kari Tanderup, and Bradley Pieters (Eds)
Environmental Radioactivity and Emergency Preparedness
Mats Isaksson and Christopher L. Rääf
The Practice of Internal Dosimetry in Nuclear Medicine
Michael G. Stabin
Radiation Protection in Medical Imaging and Radiation Oncology
Richard J. Vetter and Magdalena S. Stoeva (Eds)
Statistical Computing in Nuclear Imaging
Arkadiusz Sitek
The Physiological Measurement Handbook
John G. Webster (Ed)
Radiosensitizers and Radiochemotherapy in the Treatment of Cancer
Shirley Lehnert
Diagnostic Endoscopy
Haishan Zeng (Ed)
Medical Equipment Management
Keith Willson, Keith Ison, and Slavik Tabakov
Advanced MR Neuroimaging
from Theory to Clinical Practice
Ioannis Tsougos
Assistant Professor of Medical Physics
Faculty of Medicine, School of Health Sciences,
University of Thessaly
Biopolis, Larissa, Greece
MATLAB® and Simulink® are trademarks of the MathWorks, Inc. and are used with permission. The MathWorks does not warrant the accuracy of the text or exercises in this book. This book’s use or discussion of MATLAB® and Simulink® software or related products does not constitute endorsement or sponsorship by the MathWorks of a particular pedagogical approach or particular use of the MATLAB® and Simulink® software.
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2018 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed on acid-free paper
International Standard Book Number-13: 978-1-4987-5523-8 (Hardback)
This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www. copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750- 8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.
Library of Congress Cataloging in Publication Data
Names: Tsougos, Ioannis, author.
Title: Advanced MR neuroimaging : from theory to clinical practice / Ioannis Tsougos. Other titles: Series in medical physics and biomedical engineering.
Description: Boca Raton, FL : CRC Press, Taylor & Francis Group, [2018] |
Series: Series in medical physics and biomedical engineering | Includes bibliographical references and index. Identifiers: LCCN 2017037811| ISBN 9781498755238 (hardback ; alk. paper) |
ISBN 1498755232 (hardback ; alk. paper) | ISBN 9781498755252 (e-book) | ISBN 1498755259 (e-book)
Subjects: LCSH: Brain–Magnetic resonance imaging. | Magnetic resonance imaging. Classification: LCC RC386.6.M34 T73 2018 | DDC 616.8/04754–dc23
LC record available at https://lccn.loc.gov/2017037811
Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com
and the CRC Press Web site at http://www.crcpress.com
Contents
Series Preface |
............................................................................................................. |
|
xi |
|
Preface |
.................................................................................................................... |
|
|
xiii |
About the Author..................................................................................................... |
|
xv |
||
1 Diffusion MR Imaging |
|
|
||
1.1 |
Introduction ......................................................................................................................................... |
|
1 |
|
|
1.1.1 |
Diffusion |
|
1 |
................................................................... |
1.1.2 |
Diffusion in Magnetic Resonance Imaging |
2 |
|
1.2 ...............................................................................................Diffusion Imaging: Basic Principles |
|
3 |
||
........................................................................................... |
1.2.1 |
Diffusion - Weighted Imaging |
|
3 |
|
1.2.2 |
The b - Value |
|
5 |
........................................................................................ |
1.2.3 |
Apparent Diffusion Coefficient |
8 |
|
............................................................................... |
1.2.4 |
Isotropic or Anisotropic Diffusion? |
10 |
|
........................................................................................................ |
1.2.5 |
Echo Planar Imaging |
|
12 |
................................................................................................ |
1.2.6 |
Main Limitations of DWI |
|
13 |
1.3 ............................................................................................................... |
Diffusion Tensor Imaging |
|
14 |
1.3.1“Rotationally Invariant” Parameters (Mean Diffusivity and Fractional
|
|
Anisotropy) |
|
17 |
|
1.3.2 |
Fiber Tractography |
|
19 |
1.4 |
Conclusions and Future Perspectives.......................................................................................... |
|
22 |
|
References ...................... |
23 |
2 Artifacts and Pitfalls in Diffusion MRI
2.1 |
Introduction..................................................................................................................................... |
29 |
|
2.2 |
Artifacts and Pitfalls Categorization........................................................................................... |
30 |
|
2.3 |
Artifacts from the Gradient System............................................................................................. |
30 |
|
|
2.3.1 |
Eddy Current Artifacts................................................................................................... |
30 |
|
2.3.2 |
Eddy Currents—Mitigating Strategies......................................................................... |
32 |
2.4 |
Motion Artifacts.............................................................................................................................. |
33 |
|
|
2.4.1 |
Motion Artifacts—Mitigating Strategies..................................................................... |
35 |
|
2.4.2 |
EPI Specific Artifacts....................................................................................................... |
35 |
|
2.4.3 |
Distortions Originating from B0 Inhomogeneities.................................................... |
36 |
|
2.4.4 |
Misregistration Artifacts from Eddy Currents and Subject Motion....................... |
36 |
|
2.4.5 |
Mitigating Strategies—EPI Specific.............................................................................. |
37 |
2.5 |
Artifacts Due to Properties of the Subject Being Imaged and “Physiological” Noise.......... |
38 |
|
|
2.5.1 |
Susceptibility-Induced Distortions............................................................................... |
38 |
|
2.5.2 |
Physiological Noise.......................................................................................................... |
38 |
vi |
|
|
Contents |
2.5.3 |
Susceptibility Effects and Physiological Noise—Mitigating Strategies |
................... 39 |
|
2.6 Processing and Interpretation Pitfalls |
......................................................................................... |
40 |
|
2.6.1 |
Preprocessing of Data...................................................................................................... |
|
40 |
2.6.2 |
Quantitation of Parameters............................................................................................ |
|
42 |
2.6.3 |
Dependence of Estimated Mean Diffusivity on b-Factor.......................................... |
45 |
|
2.6.4 |
Effect on ROI Positioning and Bias on Parametric Maps.......................................... |
45 |
|
2.6.5 |
CSF Contamination in Tract Specific Measurements................................................ |
47 |
|
2.6.6 |
Intrasubject and Intersubject Comparisons................................................................ |
47 |
|
2.7 Mitigating Strategies—Available Methods and Software for Diffusion Data Correction... 48 |
|||
2.7.1 |
RESTORE Algorithm...................................................................................................... |
|
48 |
2.7.2 |
ExploreDTI |
|
49 |
2.7.3 |
FSL-FDT |
|
49 |
2.7.4 |
FreeSurfer—TRACULA.................................................................................................. |
|
49 |
2.7.5 |
TORTOISE |
|
50 |
2.8Conclusion........................................................................................................................................ 50
References |
...................... 50 |
||||
3 Perfusion MR Imaging |
|
|
|||
3.1 |
Introduction..................................................................................................................................... |
|
|
55 |
|
3.2 |
DSC MRI.......................................................................................................................................... |
|
|
56 |
|
|
3.2.1 |
DSC Imaging Explained................................................................................................. |
|
58 |
|
|
3.2.2 |
DSC Perfusion Parameters: CBV, CBF, MTT.............................................................. |
58 |
||
|
|
3.2.2.1 |
CBV |
|
58 |
|
|
3.2.2.2 |
CBF |
|
60 |
|
|
3.2.2.3 |
MTT |
|
.61 |
3.3 |
DCE-MRI......................................................................................................................................... |
|
|
.61 |
|
|
3.3.1 |
DCE Imaging Explained................................................................................................. |
|
62 |
|
3.4 |
ASL ...................... |
66 |
|||
|
3.4.1 |
ASL Imaging Explained.................................................................................................. |
|
66 |
|
|
3.4.2 |
Different ASL Techniques............................................................................................... |
|
66 |
|
|
|
3.4.2.1 |
CASL and pCASL........................................................................................... |
|
67 |
|
|
3.4.2.2 |
PASL |
|
68 |
|
|
3.4.2.3 |
VSASL |
|
68 |
|
3.4.3 |
ASL beyond CBF Estimation.......................................................................................... |
|
69 |
|
3.5 |
Conclusions and Future Perspectives.......................................................................................... |
|
69 |
||
References ...................... |
70 |
||||
4 Artifacts and Pitfalls of Perfusion MRI |
|
||||
4.1 |
Introduction..................................................................................................................................... |
|
|
75 |
|
4.2 |
Dynamic Susceptibility Contrast (DSC) Imaging Limitations............................................... |
76 |
|||
|
4.2.1 |
Subject Motion |
|
76 |
|
|
4.2.2 |
Relationship between MR Signal and Contrast Concentration............................... |
76 |
||
|
4.2.3 |
Bolus Delay and Dispersion............................................................................................ |
|
77 |
|
|
4.2.4 |
BBB Disruption and Leakage Correction.................................................................... |
77 |
||
|
4.2.5 |
Absolute versus Relative Quantification...................................................................... |
78 |
||
4.3 |
Dynamic Contrast Enhancement (DCE) Imaging Limitations............................................... |
79 |
|||
|
4.3.1 |
Suitability of Tumor Lesions.......................................................................................... |
|
79 |
|
|
4.3.2 |
Subject Motion |
|
79 |
|
|
4.3.3 |
Estimation of Arterial Input Function (AIF).............................................................. |
79 |
||
|
4.3.4 |
Temporal and Spatial Resolutions................................................................................. |
|
80 |
|
|
4.3.5 |
Variability of Results According to the Models Used................................................ |
80 |
Contents |
|
|
vii |
4.3.6 |
Quality Assurance |
|
80 |
4.4 Arterial Spin Labeling (ASL) Imaging Limitations................................................................... |
.81 |
||
4.4.1 |
Subject Motion |
|
.81 |
4.4.2 |
Physiological Signal Variations...................................................................................... |
|
82 |
4.4.3 |
Magnetic Susceptibility Artifacts.................................................................................. |
|
83 |
4.4.4 |
Coil Sensitivity Variations.............................................................................................. |
|
84 |
4.4.5 |
Labeling Efficiency........................................................................................................... |
|
84 |
4.4.6 |
Transit Time Effects......................................................................................................... |
|
84 |
4.4.7 |
Errors from Quantification Models.............................................................................. |
85 |
|
4.5 Conclusions and Future Perspectives.......................................................................................... |
|
85 |
|
References ...................... |
86 |
5
6
Magnetic Resonance Spectroscopy
5.1 |
Introduction..................................................................................................................................... |
|
.91 |
|
5.2 |
MRS Basic Principles Explained................................................................................................... |
|
93 |
|
|
5.2.1 |
Technical Issues |
|
95 |
|
5.2.2 |
Data Acquisition |
|
95 |
|
5.2.3 |
Field Strength (B0) |
|
98 |
|
5.2.4 |
Voxel Size Dependency.................................................................................................. |
|
100 |
|
5.2.5 |
Shimming |
|
101 |
|
5.2.6 |
Water and Lipid Suppression Techniques................................................................... |
102 |
|
5.3 |
MRS Metabolites and Their Biological and Clinical Significance.......................................... |
104 |
||
|
5.3.1 |
Myo-Inositol |
|
104 |
|
5.3.2 |
Choline-Containing Compounds................................................................................ |
106 |
|
|
5.3.3 |
Creatine and Phosphocreatine...................................................................................... |
107 |
|
|
5.3.4 |
Glutamate and Glutamine............................................................................................. |
|
107 |
|
5.3.5 |
N-Acetyl Aspartate |
|
107 |
|
5.3.6 |
Lactate and Lipids |
|
108 |
|
5.3.7 |
Less Commonly Detected Metabolites........................................................................ |
108 |
|
5.4 |
MRS Quantification and Data Analysis..................................................................................... |
110 |
||
|
5.4.1 |
Quantification |
|
110 |
|
5.4.2 |
Post Processing Techniques........................................................................................... |
|
.111 |
5.5 |
Quality Assurance in MRS........................................................................................................... |
|
113 |
5.6Conclusion....................................................................................................................................... 113
References ..................... |
114 |
Artifacts and Pitfalls of MRS
6.1 |
Introduction.................................................................................................................................... |
|
|
123 |
|
6.2 |
Artifacts and Pitfalls...................................................................................................................... |
|
124 |
||
|
6.2.1 |
Effects of Patient Movement.......................................................................................... |
|
124 |
|
|
6.2.2 |
Field Homogeneity and Linewidth............................................................................... |
|
124 |
|
|
6.2.3 |
Frequency Shifts and Temperature Variations........................................................... |
125 |
||
|
6.2.4 |
Voxel Positioning |
|
126 |
|
|
6.2.5 |
Use of Contrast and Positioning in MRS.................................................................... |
128 |
||
|
6.2.6 |
Chemical Shift Displacement........................................................................................ |
|
129 |
|
|
6.2.7 |
Spectral Contamination or Voxel Bleeding................................................................ |
130 |
||
|
6.2.8 |
To Quantify or Not to Quantify?.................................................................................. |
|
131 |
|
|
|
6.2.8.1 |
Relative Quantification................................................................................ |
|
131 |
|
|
6.2.8.2 |
Absolute Quantification............................................................................... |
|
132 |
|
6.2.9 |
Available Software Packages for Quantification and Analysis of MRS Data........ |
134 |
||
|
|
6.2.9.1 |
LCModel |
|
134 |
viii |
|
|
Contents |
6.2.9.2 |
jMRUI |
|
135 |
6.2.9.3 |
TARQUIN |
|
135 |
6.2.9.4 |
SIVIC |
|
136 |
6.2.9.5AQSES 137
6.3Conclusion.......................................................................................................................................138
References ..................... |
138 |
||||
7 Functional Magnetic Resonance Imaging (fMRI) |
|
||||
7.1 |
Introduction.................................................................................................................................... |
|
|
141 |
|
|
7.1.1 |
What Is Functional Magnetic Resonance Imaging (fMRI) of the Brain?.............. |
141 |
||
|
7.1.2 |
Blood Oxygenation Level Dependent (BOLD) fMRI................................................ |
142 |
||
|
7.1.3 |
fMRI Paradigm Design and Implementation............................................................ |
144 |
||
|
|
7.1.3.1 |
Blocked versus Event-Related Paradigms.................................................. |
145 |
|
|
|
7.1.3.2 |
Mixed Paradigm Designs............................................................................ |
146 |
|
7.2 |
fMRI Acquisitions—MR Scanning Sequences.......................................................................... |
148 |
|||
|
7.2.1 |
Spatial Resolution |
|
148 |
|
|
7.2.2 |
Temporal Resolution...................................................................................................... |
|
148 |
|
|
7.2.3 |
Pulse Sequences Used in fMRI..................................................................................... |
|
149 |
|
7.3 |
Analysis and Processing of fMRI Experiments........................................................................ |
151 |
|||
|
7.3.1 |
fMRI Datasets |
|
151 |
|
|
7.3.2 |
Data Preprocessing |
|
152 |
|
|
|
7.3.2.1 |
Slice-Scan Timing Correction.................................................................... |
152 |
|
|
|
7.3.2.2 |
Head Motion Correction............................................................................. |
152 |
|
|
|
7.3.2.3 |
Distortion Correction.................................................................................. |
|
153 |
|
|
7.3.2.4 |
Spatial and Temporal Smoothing............................................................... |
153 |
|
|
7.3.3 |
Statistical Analysis |
|
153 |
|
7.4 |
Pre-Surgical Planning with fMRI............................................................................................... |
|
154 |
||
7.5 |
Resting State fMRI......................................................................................................................... |
|
154 |
||
|
7.5.1 |
Resting State fMRI Procedure...................................................................................... |
|
155 |
|
7.6 |
Conclusion and the Future of fMRI............................................................................................ |
|
156 |
||
References ..................... |
157 |
||||
8 Artifacts and Pitfalls of fMRI |
|
|
|||
8.1 |
Introduction to Quantitative fMRI Limitations....................................................................... |
161 |
|||
8.2 |
Image Acquisition Limitations.................................................................................................... |
|
162 |
||
|
8.2.1 |
Spatial and Temporal Resolution.................................................................................. |
|
162 |
|
|
8.2.2 |
Spatial and Temporal fMRI Resolution—Mitigating Strategies............................. |
164 |
||
|
8.2.3 |
EPI-Related Image Distortions..................................................................................... |
|
166 |
|
8.3 |
Physiological Noise and Motion Limitations............................................................................. |
167 |
|||
|
8.3.1 |
Physiological Noise—Mitigating Strategies................................................................ |
169 |
||
|
|
8.3.1.1 |
Cardiac Gating.............................................................................................. |
|
169 |
|
|
8.3.1.2 |
Acquisition-Based Image Corrections....................................................... |
170 |
|
|
|
8.3.1.3 |
Calibration |
|
170 |
8.4 |
Interpretation Limitations............................................................................................................ |
|
171 |
||
8.5 |
Quality Assurance in fMRI.......................................................................................................... |
|
173 |
8.6Conclusion.......................................................................................................................................174
References ..................... |
174 |
9 The Role of Multiparametric MR Imaging—Advanced MR Techniques in the Assessment of Cerebral Tumors
9.1 |
Introduction.................................................................................................................................... |
179 |
Contents |
|
|
ix |
9.2 |
Gliomas |
............. 181 |
|
|
9.2.1 |
DWI Contribution in Gliomas...................................................................................... |
183 |
|
9.2.2 |
DTI Contribution in Gliomas....................................................................................... |
186 |
|
9.2.3 |
Perfusion Contribution in Gliomas............................................................................. |
187 |
|
9.2.4 |
MRS Contribution in Gliomas...................................................................................... |
188 |
9.3 |
Cerebral Metastases....................................................................................................................... |
189 |
|
|
9.3.1 |
DWI/DTI Contribution in Metastases........................................................................ |
191 |
|
9.3.2 |
Perfusion Contribution in Metastases......................................................................... |
193 |
|
9.3.3 |
MRS Contribution in Metastases................................................................................. |
193 |
9.4 |
Meningiomas.................................................................................................................................. |
194 |
|
|
9.4.1 |
DWI/DTI Contribution in Meningiomas................................................................... |
194 |
|
9.4.2 |
Perfusion Contribution in Meningiomas.................................................................... |
196 |
|
9.4.3 |
MRS Contribution in Meningiomas............................................................................ |
197 |
9.5 |
Primary Cerebral Lymphoma...................................................................................................... |
198 |
|
|
9.5.1 |
DWI/DTI Contribution in PCLs.................................................................................. |
198 |
|
9.5.2 |
Perfusion Contribution in PCLs................................................................................... |
198 |
|
9.5.3 |
MRS Contribution in PCLs........................................................................................... |
199 |
9.6 |
Intracranial Abscesses.................................................................................................................. |
200 |
|
|
9.6.1 |
DWI DTI Contribution in Abscesses......................................................................... |
200 |
|
9.6.2 |
Perfusion Contribution in Abscesses........................................................................... |
201 |
|
9.6.3 |
MRS Contribution in Abscesses.................................................................................. |
202 |
9.7 |
Summary and Conclusion........................................................................................................... |
202 |
|
References .................... |
203 |
Index 215
Series Preface
The Series in Medical Physics and Biomedical Engineering describes the applications of physical sciences, engineering, and mathematics in medicine and clinical research.
The series seeks (but is not restricted to) publications in the following topics:
• |
Artificial organs |
• |
Medical/surgical devices |
• |
Assistive technology |
• |
Patient monitoring |
• |
Bioinformatics |
• |
Physiological measurement |
• |
Bioinstrumentation |
• |
Prosthetics |
• |
Biomaterials |
• |
Radiation protection, health |
• |
Biomechanics |
• |
physics, and dosimetry |
• |
Biomedical engineering |
• |
Regulatory issues |
• |
Clinical engineering |
• |
Rehabilitation engineering |
• |
Imaging |
• |
Sports medicine |
• |
Implants |
• |
Systems physiology |
• |
Medical computing and |
• |
Telemedicine |
|
mathematics |
• |
Tissue engineering |
|
|
• |
Treatment |
The Series in Medical Physics and Biomedical Engineering is an international series that meets the need for up-to-date texts in this rapidly developing field. Books in the series range in level from introductory graduate textbooks and practical handbooks to more advanced expositions of current research.
The Series in Medical Physics and Biomedical Engineering is the official book series of the International Organization for Medical Physics.
The International Organization for Medical Physics
The International Organization for Medical Physics (IOMP) represents over 18,000 medical physicists worldwide and has a membership of 80 national and 6 regional organizations, together with a number of corporate members. Individual medical physicists of all national member organisations are also automatically members.
The mission of IOMP is to advance medical physics practice worldwide by disseminating scientific and technical information, fostering the educational and professional development of medical physics and promoting the highest quality medical physics services for patients.
A World Congress on Medical Physics and Biomedical Engineering is held every three years in cooperation with International Federation for Medical and Biological Engineering (IFMBE)
xi
xii |
Series Preface |
and International Union for Physics and Engineering Sciences in Medicine (IUPESM). A regionally based international conference, the International Congress of Medical Physics (ICMP) is held between world congresses. IOMP also sponsors international conferences, workshops and courses.
The IOMP has several programmes to assist medical physicists in developing countries. The joint IOMP Library Programme supports 75 active libraries in 43 developing countries, and the Used Equipment Programme coordinates equipment donations. The Travel Assistance Programme provides a limited number of grants to enable physicists to attend the world congresses.
IOMP co-sponsors the Journal of Applied Clinical Medical Physics. The IOMP publishes, twice a year, an electronic bulletin, Medical Physics World. IOMP also publishes e-Zine, an electronic news letter about six times a year. IOMP has an agreement with Taylor & Francis for the publication of the Medical Physics and Biomedical Engineering series of textbooks. IOMP members receive a discount.
IOMP collaborates with international organizations, such as the World Health Organisations (WHO), the International Atomic Energy Agency (IAEA) and other international professional bodies such as the International Radiation Protection Association (IRPA) and the International Commission on Radiological Protection (ICRP), to promote the development of medical physics and the safe use of radiation and medical devices.
Guidance on education, training and professional development of medical physicists is issued by IOMP, which is collaborating with other professional organizations in development of a professional certification system for medical physicists that can be implemented on a global basis.
The IOMP website (www.iomp.org) contains information on all the activities of the IOMP, policy statements 1 and 2 and the ‘IOMP: Review and Way Forward’ which outlines all the activities of IOMP and plans for the future.
Preface
Since its early medical application about 40 years ago, magnetic resonance imaging has revolutionized brain neuroimaging, providing non-invasively excellent high-resolution images without the use of ionizing radiation.
Nevertheless, despite the superior quality, conventional MR imaging provides only anatomical, rather than physiological, information and may therefore be sometimes non-specific.
During the last decade, some of the greatest achievements in neuroimaging have been related to remarkable advances in MR techniques, which provided insights into tissue microstructure, microvasculature, metabolism, and brain connectivity. These advanced MR neuroimaging techniques include diffusion, perfusion, magnetic resonance spectroscopy, and functional MRI.
Previously available mostly in research environments, they are now establishing themselves firmly in the everyday clinical practice in a plethora of clinical MR systems. However, despite the growing interest and wider acceptance, the lack of a comprehensive body of knowledge, the intrinsic complexity and physical difficulty of the techniques, as well as an appreciable number of associated artifacts and pitfalls, still confine their routine clinical application.
This book focuses on the basic principles and physics theory of diffusion, perfusion, magnetic resonance spectroscopy, and functional MRI, accompanied by their clinical applications, with particular emphasis on the associated artifacts and pitfalls using a comprehensive and didactic approach. It aims to bridge the gap between theoretical applications and optimized clinical practice of advanced techniques by addressing all of them in a single and concise volume.
The book is organized in nine chapters. Four chapters (Chapters 1, 3, 5, and 7) describe the basic principles of the discussed techniques, providing an overview of the methods with a step-by-step didactic approach, explaining fundamentals as well as clinical implications. These are, followed by respective dedicated chapters on the potential artifacts and pitfalls of each technique, including the proposed mitigating strategies, with special attention in the postprocessing techniques (Chapters 2, 4, 6, and 8).
The final chapter (Chapter 9) covers a multiparametric approach utilizing all the aforementioned advanced MR techniques, evaluating the different underlying patho-physiological characteristics of brain tumors in an attempt to illustrate the potential ability of these techniques to contribute to a more accurate diagnosis.
Each chapter, as well as several important sections within each chapter, begins with a dedicated “Focus Point” box, “sensitizing” the reader’s attention to the key features, by highlighting the most important concepts that follow. An introduction in every chapter further guides the reader into the forthcoming more detailed information. Lastly, summary tables and aggregated classifications are used in an attempt to facilitate memorization, supporting those who wish to delve into and apply these techniques in the clinical routine.
xiii
xiv |
Preface |
The book can serve as an educational manual for neuroimaging researchers and basic scientists (radiologists, neurologists, neurosurgeons, medical physicists, engineers, etc.) with an interest in advanced MR techniques, as well as a reference for experienced clinical scientists who wish to optimize their multi-parametric imaging approach.
In conclusion, I sincerely hope this is an easy-to-read yet comprehensive handbook, which can be used as an essential guide to the advanced MR imaging techniques routinely used in clinical practice for the diagnosis and follow-up of patients with brain tumours.
Ioannis Tsougos
Assistant Professor of Medical Physics
Medical School, University of Thessaly
About the Author
Dr. Ioannis Tsougos holds a BSc in physics, and an MSc and a PhD in medical radiation physics. Currently, he is an assistant professor of Medical Radiation Physics at the medical school of the University of Thessaly, Larissa, Greece and a visiting researcher in the Neuroimaging Division at the Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom. He has authored more than 75 research papers and 10 international book chapters. In addition, he frequently acts as a reviewer for several journals in medical physics/radiology and European research foundations projects. Dr. Tsougos has broad multidisciplinary teaching and clinical experience, specializing in advanced MR techniques, and he is a member of the EFOMP, ESR, and ESMRMB.
xv